Relay Therapeutics

Relay Therapeutics announced updated clinical data for RLY-2608 + fulvestrant in PI3Kα-mutated breast cancer at the San Antonio Breast Cancer Symposium. A conference call is scheduled for December 11, 2024, at 7am ET. RLY-2608, a mutant-selective PI3Kα inhibitor, aims to treat over 300,000 patients annually in the U.S.

Relay Therapeutics and Elevar Therapeutics announce global licensing agreement for lirafugratinib, a selective FGFR2 inhibitor for FGFR2-driven cholangiocarcinoma and other solid tumors. Elevar assumes development and commercialization, with Relay eligible for $75M in milestones and royalties.

Relay Therapeutics and Elevar Therapeutics announce global licensing agreement for lirafugratinib, a selective oral FGFR2 inhibitor for FGFR2-driven cholangiocarcinoma and other solid tumors. The agreement follows positive FDA interactions and differentiated data. Elevar assumes full development and commercialization responsibilities, with Relay eligible for up to $500 million in milestones and royalties.

Relay Therapeutics and Elevar Therapeutics announce a global licensing agreement for lirafugratinib (RLY-4008), a potential best-in-class FGFR2 inhibitor for FGFR2-driven cholangiocarcinoma and other FGFR2-altered solid tumors. Elevar will assume full development and commercialization responsibilities, with Relay eligible for up to $500 million in milestone payments and royalties.

Relay Therapeutics and Elevar Therapeutics announce exclusive global licensing agreement for lirafugratinib, a potential best-in-class FGFR2 inhibitor for FGFR2-driven cholangiocarcinoma and other solid tumors. Elevar receives worldwide development and commercialization rights, while Relay can earn up to $500 million in payments, including $75 million upfront and regulatory milestones, plus double-digit royalties on global sales. The FDA has granted lirafugratinib breakthrough therapy and orphan drug designations, recommending an NDA for FGFR2-driven CCA first, followed by a supplemental NDA for other solid tumors.

Niven R. Narain emphasizes that AI investments in drug development require robust data and validation. GEN's A-List highlights 10 AI-based drug discovery leaders, including BPGbio, which focuses on cancer energy generation. Other notable companies include Nvidia and Palantir Technologies, though not on the A-List. The list includes specifics on companies like Anima Biotech, Atomwise, and Nimbus Therapeutics, detailing their AI platforms and drug development progress.

Vertex Pharmaceuticals reported Q3 2024 revenue of $2.77B, up 12% YoY, driven by TRIKAFTA®/KAFTRIO® therapies. The company raised its full-year revenue guidance to $10.8B-$10.9B, with three programs entering Phase 3 clinical development. Vertex's strong cash position of $11.2B supports its R&D and commercialization efforts, positioning it for multiple product launches and pipeline advancements.

Relay Therapeutics to report Q3 2024 financial results and highlights on Nov 6, 2024, after U.S. markets close. The company focuses on precision medicine using computational and experimental technologies for drug discovery.

RLY-2608, an oral, mutant-selective PI3Kα allosteric inhibitor, addresses off-target toxicities of existing modulators like alpelisib and inavolisib. It is in Phase I for HR+/HER2- breast cancer treatment with fulvestrant.

H.C. Wainwright maintains Buy rating on Relay Therapeutics (NASDAQ:RLAY) with $19.00 price target, following FDA approval of Roche's Itovebi for breast cancer treatment. The approval is based on the INAVO120 trial, showing significant reduction in disease progression or death with combination therapy. Relay Therapeutics' share value is expected to benefit from clinical advancements and regulatory milestones in oncology. The company also reported promising Phase 1 ReDiscover trial results and initiated a $200 million public offering.